This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Canada Approves ABRAXANE® Plus Gemcitabine For First-Line Treatment Of Patients With Metastatic Pancreatic Cancer

Stocks in this article: CELG









High unmet need addressed with first new approved treatment in eighteen years



MISSISSAUGA, ON, August 6, 2014 /CNW/ - Health Canada has approved PrABRAXANE ® for Injectable Suspension (paclitaxel powder for injectable suspension) (nanoparticle, albumin-bound [nab ®] paclitaxel) for first-line treatment of adult patients with metastatic pancreatic cancer. The approval is welcome news for Canadians who are diagnosed with metastatic pancreatic cancer, and represents the first approved treatment for this disease in nearly two decades.

The Health Canada approval was based on the results of MPACT (Metastatic Pancreatic Adenocarcinoma Clinical Trial), an open-label, phase III, randomized, international study which was published in the New England Journal of Medicine in October 2013.  The MPACT study involved 861 chemotherapy-naïve patients with metastatic pancreatic cancer from 11 countries, including Canada, and showed a statistically significant improvement in median overall survival with ABRAXANE plus gemcitabine compared to gemcitabine alone (8.5 vs. 6.7 months) (HR 0.72, P<0.0001); a 28% overall reduction in risk of death. 1



"This is a cancer where there are few effective treatments and the first-line approval of ABRAXANE in combination with gemcitabine represents an important advance," said. Dr. Malcolm J. Moore, Program Head, Medical Oncology and Hematology and Director, McCain Centre for Pancreatic Cancer at the Princess Margaret Cancer Centre, University Health Network in Toronto and an investigator in the MPACT trial. "This approval will certainly have an impact on the way physicians manage this disease in the future.  Pancreatic cancer is a tough one to deal with; patients are desperate and physicians are on the lookout for new advances. The addition of ABRAXANE to gemcitabine has demonstrated significant benefits in overall survival and this gives our patients hope."

"It's been quite some time since we've seen any type of treatment advance for pancreatic cancer making this news so important for patients.  This will give patients the hope that is needed to continue to fight," said Laurie Ellies, Co-founder, and Acting Executive Director of Pancreatic Cancer Canada.  "Over the past decade, there has been a significant improvement in cancer survival rates. Sadly, the same cannot be said about pancreatic cancer.  We're dealing with a deadly disease. For a person diagnosed with metastatic disease it can be a question of weeks. This year alone, we can expect an estimated 4,700 Canadians will be diagnosed with this disease.  If anything, this number tells us that we are desperately in need of more research and treatments - patients are counting on it."

ABRAXANE is commercially available in Canada.

About Pancreatic CancerPancreatic cancer is the fourth-leading cause of cancer-related death in Canada. 2 The pancreas is composed of two main cell types: exocrine and endocrine. Adenocarcinoma is a sub-type of exocrine tumors and accounts for about 95% of cancers of the pancreas. 3 For all stages of pancreatic cancer combined, the five-year survival rate in Canada is about 8%. For metastatic pancreatic cancer, the five-year survival is approximately 2% in Canada. 2



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs